The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto).
Gunter Von Minckwitz
Honoraria - Roche; Sanofi
Andreas Schneeweiss
No relevant relationships to disclose
Christoph Salat
No relevant relationships to disclose
Mahdi Rezai
No relevant relationships to disclose
Dirk Michael Zahm
No relevant relationships to disclose
Peter Klare
No relevant relationships to disclose
Jens U. Blohmer
No relevant relationships to disclose
Hans Tesch
No relevant relationships to disclose
Fariba Khandan
No relevant relationships to disclose
Sebastian Jud
No relevant relationships to disclose
Christian Jackisch
Honoraria - Roche; Sanofi
Keyur Mehta
No relevant relationships to disclose
Sibylle Loibl
No relevant relationships to disclose
Michael Untch
No relevant relationships to disclose